Catalyst Biosciences - Chart Of The Day
The Chart of the Day belongs to Catalysts Biosciences (CBIO). I found the biomedical stock by using Barchart to sort the Top Stocks to Own list first by the highest Weighted Alpha, then I used the Flipchart feature to review the charts for consistent price appreciation. Since the Trend Spotter signaled a buy on 11/20 the stock gained 206.89%.
Catalyst Biosciences, Inc. is a biopharmaceutical company which focused on creating and developing medicines to address serious medical conditions. The Company's hemostasis product candidates include CB 813d/PF-0520602, CB 2679d/ISU 304 and FXa. Anti-Complement Product consists of CB 2782 and Ophthalmic which are in clinical different trail. Catalyst Biosciences, Inc., formerly known as Targacept, Inc., is based in South San Francisco, Calif.
Barchart's Opinion trading systems are listed below. Please note that the Barchart Opinion indicators are updated live during the session every 10 minutes and can therefore change during the day as the market fluctuates. The indicator numbers shown below therefore may not match what you see live on the web site when you read this report.
Barchart technical indicators:
- 150.22+ Weighted Alpha
- 100% technical buy signals
- Trend Spotter buy signal
- Above its 20, 50 and 100 day moving averages
- 9 new highs and up 77.39% in the last month
- Relative Strength Index 79.35%
- Technical support level at 14.86
- Recently traded at 18.61 with a 50 day moving average of 9.73
Fundamental factors:
- Market Cap $99 million
- Revenue expected to grow 103.00% this year and another 125.90% next year
- Earnings estimated to increase 63.10% this year and an additional 36.00% next year
- Wall Street analysts issued 1 strong buy and 1 buy recommendation on the stock
Disclosure: None.
I think the shares have gotten a bit ahead of themselves for now, but it is a promising company. I appreciate your article on it. Let's see what news and scientific progress they make to see if they can move up from here.
Sadly if you missed out on this it is a bit too late as most of the biotech market is already run up. That said, long term they still could be worth it. You need to do serious research to see if the company you are picking will be a long term value play or not.
Thanks Moon, so you'd advice against $CBIO?